Instrument Inactif

Gouvernance TapImmune Inc. OTC Bulletin Board

TPIV

US8760334081

Recherche biotechnologique et médicale

Comité Exécutif: TapImmune Inc.

Dirigeant

Fonctions occupéesDepuis

Juan Vera

46 ans

Chief Executive Officer	01/05/2023
President	01/05/2023
Corporate Secretary	-
Treasurer	-

Elizabeth Donnelly

Chief Administrative Officer

01/09/2015

Kenneth Ray Moseley

69 ans

General Counsel

23/10/2018

Gerald Garrett

61 ans

Chief Tech/Sci/R&D Officer

01/11/2019

Edmund Cheung

Human Resources Officer

01/01/2021

Monic Stuart

Chief Tech/Sci/R&D Officer

08/05/2023

Patricia Allison

Chief Tech/Sci/R&D Officer

Maria-Bernadette Madel

36 ans

Chief Operating Officer

01/12/2023

Mary Newman

67 ans

General Counsel

Composition du Conseil d'Administration: TapImmune Inc.

Administrateur

ComitésDepuis

Norman Eansor

65 ans

Audit Committee Chair	24/05/2022
Compensation Committee Chair	24/05/2022

Steven Elms

62 ans

Governance Committee	06/08/2019
Nominating Committee	06/08/2019
Audit Committee	06/08/2019
Compensation Committee	19/05/2020

Kathryn Corzo

65 ans

Audit Committee
Governance Committee
Nominating Committee

Katharine Knobil

62 ans

Compensation Committee	26/08/2024
Governance Committee Chair	08/12/2021
Nominating Committee Chair

Juan Vera

46 ans

Director/Board Member

17/10/2018

Anciens Dirigeants et Administrateurs: TapImmune Inc.

Insider

Fonctions occupées

DepuisJusqu'au

John Wilson

Director/Board Member	17/10/2018	24/01/2025
Chief Executive Officer	-	-
Independent Dir/Board Member	17/10/2018	24/01/2025

Tsvetelina Hoang

Chief Tech/Sci/R&D Officer

23/10/2018

01/08/2024

Nadia Agopyan

General Counsel

15/08/2019

01/03/2024

Eliot Lurier

Comptroller/Controller/Auditor	-	17/11/2023
Director of Finance/CFO	30/06/2023	17/11/2023

Ania Szymanska

Corporate Officer/Principal

01/01/2020

01/11/2023

Michael Loiacono

Comptroller/Controller/Auditor	25/08/2016	30/06/2023
Director of Finance/CFO	25/08/2016	27/11/2018
Corporate Secretary	25/08/2016	30/06/2023
Treasurer	25/08/2016	30/06/2023

David Laskow-Pooley

Director/Board Member	19/03/2015	06/06/2023
Independent Dir/Board Member	19/03/2015	06/06/2023

Peter Hoang

Director/Board Member	25/09/2017	01/05/2023
Chief Executive Officer	25/09/2017	01/05/2023
President	25/09/2017	01/05/2023

Mythili Koneru

Chief Tech/Sci/R&D Officer	01/12/2019	09/04/2023
Corporate Officer/Principal	07/02/2019	01/12/2019

Neda Safarzadeh

Investor Relations Contact	01/01/2022	01/12/2022
Public Communications Contact	01/01/2022	01/12/2022
Sales & Marketing	01/01/2022	01/12/2022

Anthony H. Kim

Director of Finance/CFO

27/11/2018

30/09/2022

Frederick Wasserman

Director/Board Member	01/01/2016	17/10/2018
Chairman	17/10/2018	24/05/2022
Independent Dir/Board Member	01/01/2016	24/05/2022

Ann Leen

Chief Tech/Sci/R&D Officer	23/10/2018	01/02/2020
Founder	23/10/2018	01/02/2020

Mark Reddish

Director/Board Member	22/11/2011	17/10/2018
Independent Dir/Board Member	22/11/2011	17/10/2018
Corporate Officer/Principal	22/11/2011	-

Sherry Grisewood

Director/Board Member	20/03/2013	17/10/2018
Independent Dir/Board Member	20/03/2013	17/10/2018

Glynn Wilson

Comptroller/Controller/Auditor	07/02/2005	-
Director/Board Member	07/02/2005	27/08/2009
Chief Executive Officer	10/09/2010	25/09/2017
Chairman	27/08/2009	17/10/2018
Director of Finance/CFO	07/02/2005	25/08/2016
Public Communications Contact	07/02/2005	25/09/2017
President	27/04/2017	25/09/2017
Corporate Secretary	07/02/2005	-

Joshua Silverman

Director/Board Member	01/08/2016	01/10/2018
Independent Dir/Board Member	01/08/2016	01/10/2018

Richard Kenney

Chief Tech/Sci/R&D Officer

06/12/2017

John Bonfiglio

Director/Board Member	23/07/2015	27/04/2017
Chief Operating Officer	18/07/2016	27/04/2017
President	18/07/2016	27/04/2017

Patrick Yeramian

Chief Tech/Sci/R&D Officer

01/02/2015

01/01/2017

Ali Behbahani

Director/Board Member

01/01/2017

James Fuller

Director/Board Member

18/05/2012

06/02/2013

Lynn M. DePippo

Director/Board Member

09/09/2010

23/08/2012

Denis Corin

Director/Board Member	09/11/2010	08/05/2012
Chief Executive Officer	01/11/2006	27/08/2009
Director of Finance/CFO	21/07/2010	08/05/2012
President	01/11/2006	08/05/2012

Robert Z. Florkiewicz

Chief Tech/Sci/R&D Officer

11/04/2012

Tracy Moore

Director of Finance/CFO

27/08/2009

16/07/2010

Alan P. Lindsay

Chairman

01/01/2007

01/07/2009

Patrick A. McGowan

Director/Board Member	05/12/2005	01/07/2009
Director of Finance/CFO	05/12/2005	-
Corporate Secretary	05/12/2005	-
Treasurer	05/12/2005	-

Terry Pearson

Director/Board Member

05/12/2005

Karl Erik Hellström

Director/Board Member

05/12/2005

Edward Farrauto

Director of Finance/CFO

01/05/2004

08/10/2005

Konstantine Sarafis

President

26/09/2005

Ronald Handford

President

07/02/2005

Timothy Z. Vitalis

Director/Board Member

01/03/2000

F. Andrew Dorr

Chief Tech/Sci/R&D Officer

Shelia Sterr

Human Resources Officer

Grant R. Atkins

Director of Finance/CFO

Venissa Izaguirre

Corporate Officer/Principal

Larry Morningstar

Public Communications Contact

11/12/2009

James Dale Davidson

Director of Finance/CFO	-	-
Corporate Secretary	-	-

Aris Morfopoulos

Chief Executive Officer	-	-
President	-	-

Wilfred Jefferies

Chairman	-	31/08/2009
Chief Tech/Sci/R&D Officer	-	-

Norman MacKinnon

Director/Board Member

Thad Morris

Investor Relations Contact	-	-
Public Communications Contact	-	-

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	9
Femme	4

Dont comité exécutif

Homme	6
Femme	3

Dont Administrateurs

Homme	4
Femme	1

Marker Therapeutics, Inc. est une société spécialisée dans l'immuno-oncologie, au stade clinique, qui se consacre au développement et à la commercialisation d'immunothérapies innovantes à base de lymphocytes T pour le traitement des hémopathies malignes et des tumeurs solides. La technologie des cellules T à reconnaissance multi-antigénique (MAR) de la société repose sur l’expansion sélective de cellules T non modifiées génétiquement, spécifiques à la tumeur, qui reconnaissent les antigènes associés aux tumeurs (cibles tumorales) et détruisent les cellules tumorales exprimant ces cibles. Ces cellules T sont conçues pour reconnaître plusieurs cibles tumorales afin de produire une activité antitumorale à large spectre. Elle développe deux produits candidats, dont un produit à base de cellules T MAR autologues pour le traitement du lymphome et du cancer du pancréas (MT-601) et un produit prêt à l'emploi (OTS) pour diverses indications (MT-401-OTS). Elle a développé le MT-601 pour qu'il reconnaisse plusieurs antigènes cibles exprimés par la tumeur, limitant ainsi l'adaptation de la tumeur par sélection négative des antigènes ou régulation à la baisse.

Employés

Secteur

Recherche biotechnologique et médicale

Plus d'informations sur la société